Market Closed - Toronto S.E. 10:46:09 2024-03-28 am EDT 5-day change 1st Jan Change
0.235 CAD 0.00% Intraday chart for Ceapro Inc. -2.08% +23.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share MT
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co MT
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides MT
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation CI
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 20 million in a merger of equals transaction. CI
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases MT
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases CI
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level CI
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise MT
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise CI
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation MT
Ceapro Inc. Announces Next Phase of Research Collaboration with the Angiogenesis Foundation CI
Ceapro Inc. Announces Resignation of Glenn Rourke as A Director CI
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases CI
Ceapro on Findings That Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing, Tissue Regeneration MT
Ceapro Inc. Announces Positive Results from Research Collaboration with the Angiogenesis Foundation Conducted with Researchers At the University of Arizona CI
Chart Ceapro Inc.
More charts
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.
More about the company
  1. Stock
  2. Equities
  3. Stock Ceapro Inc. - Toronto S.E.
  4. News Ceapro Inc.
  5. Ceapro Books Higher Q3 Earnings, Reports Preliminary Results from Oat Beta Glucan Clinical Trial